Literature DB >> 21735045

Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes.

Mireia Menéndez1, Joan Castellsagué, Marc Mirete, Eva Pros, Lídia Feliubadaló, Ana Osorio, Mónica Calaf, Eva Tornero, Jesús del Valle, Juana Fernández-Rodríguez, Francisco Quiles, Mónica Salinas, Angela Velasco, Alex Teulé, Joan Brunet, Ignacio Blanco, Gabriel Capellá, Conxi Lázaro.   

Abstract

Comprehensive genetic testing of the breast cancer susceptibility genes BRCA1 and BRCA2 identified approximately 16% of variants of unknown significance (VUS), a significant proportion of which could affect the correct splicing of the genes. Our aim is to establish a workflow for classifying VUS in these complex genes, the first stage of which is splicing analysis. We used a combined approach consisting of five in silico splicing prediction programs and RT-PCR analysis for a set of 26 variants not previously studied at the mRNA level and six variants that had already been studied, four of which were used as positive controls as they were found to affect the splicing of these genes and the other two were used as negative controls. We identified a splicing defect in 8 of the 26 newly studied variants and ruled out splicing alteration in the remaining 18 variants. The results for the four positive and the two negative control variants were consistent with results presented in the literature. Our results strongly suggest that the combination of RNA analysis and in silico programs is an important step towards the classification of VUS. The results revealed a very high correlation between experimental data and in silico programs when using tools for predicting acceptor/donor sites but a lower correlation in the case of tools for identifying ESE elements.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21735045     DOI: 10.1007/s10549-011-1661-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  10 in total

1.  Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort.

Authors:  Elisabeth Jarhelle; Hilde Monica Frostad Riise Stensland; Lovise Mæhle; Marijke Van Ghelue
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

2.  BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.

Authors:  Inmaculada de Juan; Sarai Palanca; Asunción Domenech; Lidia Feliubadaló; Ángel Segura; Ana Osorio; Isabel Chirivella; Miguel de la Hoya; Ana Beatriz Sánchez; Mar Infante; Isabel Tena; Orland Díez; Zaida Garcia-Casado; Ana Vega; Àlex Teulé; Alicia Barroso; Pedro Pérez; Mercedes Durán; Estela Carrasco; M José Juan-Fita; Rosa Murria; Marta Llop; Eva Barragan; Ángel Izquierdo; Javier Benítez; Trinidad Caldés; Dolores Salas; Pascual Bolufer
Journal:  Fam Cancer       Date:  2015-12       Impact factor: 2.375

3.  Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practice in standardized clinical testing.

Authors:  Phillip J Whiley; Miguel de la Hoya; Mads Thomassen; Alexandra Becker; Rita Brandão; Inge Sokilde Pedersen; Marco Montagna; Mireia Menéndez; Francisco Quiles; Sara Gutiérrez-Enríquez; Kim De Leeneer; Anna Tenés; Gemma Montalban; Demis Tserpelis; Toshio Yoshimatsu; Carole Tirapo; Michela Raponi; Trinidad Caldes; Ana Blanco; Marta Santamariña; Lucia Guidugli; Gorka Ruiz de Garibay; Ming Wong; Mariella Tancredi; Laura Fachal; Yuan Chun Ding; Torben Kruse; Vanessa Lattimore; Ava Kwong; Tsun Leung Chan; Mara Colombo; Giovanni De Vecchi; Maria Caligo; Diana Baralle; Conxi Lázaro; Fergus Couch; Paolo Radice; Melissa C Southey; Susan Neuhausen; Claude Houdayer; Jim Fackenthal; Thomas Van Overeem Hansen; Ana Vega; Orland Diez; Rien Blok; Kathleen Claes; Barbara Wappenschmidt; Logan Walker; Amanda B Spurdle; Melissa A Brown
Journal:  Clin Chem       Date:  2013-11-08       Impact factor: 8.327

4.  Comprehensive splicing functional analysis of DNA variants of the BRCA2 gene by hybrid minigenes.

Authors:  Alberto Acedo; David J Sanz; Mercedes Durán; Mar Infante; Lucía Pérez-Cabornero; Cristina Miner; Eladio A Velasco
Journal:  Breast Cancer Res       Date:  2012-05-25       Impact factor: 6.466

5.  Splicing mutation analysis reveals previously unrecognized pathways in lymph node-invasive breast cancer.

Authors:  Stephanie N Dorman; Coby Viner; Peter K Rogan
Journal:  Sci Rep       Date:  2014-11-14       Impact factor: 4.379

6.  Adding In Silico Assessment of Potential Splice Aberration to the Integrated Evaluation of BRCA Gene Unclassified Variants.

Authors:  Maxime P Vallée; Tonya L Di Sera; David A Nix; Andrew M Paquette; Michael T Parsons; Russel Bell; Andrea Hoffman; Frans B L Hogervorst; David E Goldgar; Amanda B Spurdle; Sean V Tavtigian
Journal:  Hum Mutat       Date:  2016-04-15       Impact factor: 4.878

7.  Identification of a Splice Variant (c.5074+3A>C) of BRCA1 by RNA Sequencing and TOPO Cloning.

Authors:  Jinyoung Hong; Ji Hyun Kim; Se Hee Ahn; Hyunjung Gu; Suhwan Chang; Woochang Lee; Dae-Yeon Kim; Sail Chun; Won-Ki Min
Journal:  Genes (Basel)       Date:  2021-05-26       Impact factor: 4.096

8.  Comparative in vitro and in silico analyses of variants in splicing regions of BRCA1 and BRCA2 genes and characterization of novel pathogenic mutations.

Authors:  Mara Colombo; Giovanna De Vecchi; Laura Caleca; Claudia Foglia; Carla B Ripamonti; Filomena Ficarazzi; Monica Barile; Liliana Varesco; Bernard Peissel; Siranoush Manoukian; Paolo Radice
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

Review 9.  Hereditary breast cancer: the era of new susceptibility genes.

Authors:  Paraskevi Apostolou; Florentia Fostira
Journal:  Biomed Res Int       Date:  2013-03-21       Impact factor: 3.411

10.  A unified analytic framework for prioritization of non-coding variants of uncertain significance in heritable breast and ovarian cancer.

Authors:  Eliseos J Mucaki; Natasha G Caminsky; Ami M Perri; Ruipeng Lu; Alain Laederach; Matthew Halvorsen; Joan H M Knoll; Peter K Rogan
Journal:  BMC Med Genomics       Date:  2016-04-11       Impact factor: 3.063

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.